Trea tment of polypoid choroidal vasculopathy complicated by extensive subretinal hemorrhage. A case report

P. A. Perevozchikov; D. V. Peregudov; O. Yu. Kuznetsova

doi:10.33791/2222-4408-2022-4-23-28

Trea tment of polypoid choroidal vasculopathy complicated by extensive subretinal hemorrhage. A case report

P. A. Perevozchikov, D. V. Peregudov, O. Yu. Kuznetsova

https://doi.org/10.33791/2222-4408-2022-4-23-28

Full Text:

PDF (Rus)

| HTML (Rus) Open Access

| XML (Rus) Open Access

Buy (200 RUB) |

Generate QR code

Abstract

Polypoid choroidal vasculopathy (PCV) is a type of wet form of age-related macular degeneration (AMD). It is characterized by formation aneurysmal dilations of abnormal choroidal vessels (polyps) under the retinal pigment epithelium (RPE) in the choroid. The disease leads to a vision loss due to formation of serous retinal detachment, neuroepithelium detachment and RPE, subretinal hemorrhages, ﬁbrosis, atrophy of RPE. The generally accepted treatment of PCV is antiangiogenic therapy.

The purpose of this work is to present and to analyze the clinical case of polypoid choroidal vasculopathy treatment complicated by extensive subretinal hemorrhage.

Description of the case. This clinical case of PCV in the right eye that is complicated by extensive subretinal hemorrhage on the background of antiangiogenic therapy in a 72-year-old man is presented. In addition to standard ophthalmological research methods, we performed optical coherence tomography (OCT) with Cirrus HD-OCT 5000 Zeiss (Carl Zeiss, Germany), angio-OCT with Optovue Solix High-Speed Spectral Optical Coherence Tomograph (Optovue, USA) and fundus photo registration with Topcon TRC-NW8F Retinal Camera (Topcon, Japan). The comprehensive surgical approach was applied to this patient, including posterior subtotal vitrectomy with our Stellaris PC microsurgical system (Baush&Lomb, USA) and the prourokinase subretinal injection against the background of aﬂibercept antiangiogenic therapy and removal of a concomitant cataract with implantation of an intraocular lens (IOL).

Discussion. The early treatment of this patient and at the right time procedure of microinvasive 25-G vitrectomy combined with prourokinase subretinal injection contributed to the resorption of hemorrhage in the shortest possible time and improved visual functions from 0.02 to 0.6.

Conclusions. The presented comprehensive approach of PCV treatment and its complications made possible to provide social rehabilitation of the patient and to preserve high values of visual functions in the aﬀected eye.

Keywords

polypoidal choroidal vasculopathy, age-related macular degeneration, subretinal hemorrhage

About the Authors

P. A. Perevozchikov

Tri-Z, Moscow Branch
Russian Federation

Petr A. Perevozchikov, Dr. Sci. (Med.), Ophthalmologist

3, Boris Galushkin Str., Moscow, 129301

D. V. Peregudov

Tri-Z, Moscow Branch
Russian Federation

Dmitry V. Peregudov, Head

3, Boris Galushkin Str., Moscow, 129301

O. Yu. Kuznetsova

Tri-Z, Moscow Branch
Russian Federation

Oksana Yu. Kuznetsova, Ophthalmologist

3, Boris Galushkin Str., Moscow, 129301

References

1. Ciardella A.P., Donsoff I.M., Huang S.J. et al. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49(1):25–37. https://doi.org/10.1016/j.survophthal.2003.10.007

2. Hayashi H., Yamashiro K., Gotoh N. et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2010;51:5914–5919. https://doi.org/10.1167/iovs.10-5554

3. Liu Y., Wen F., Huang S. et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2007;245:1441–1445. https://doi.org/10.1007/s00417-007-0575-8

4. Yannuzzi L.A., Sorenson J., Spaide R.F. et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8. https://doi.org/10.1097/00006982-199001010-00001

5. Sho K., Takahashi K., Yamada H. et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121(10):1392–1396. https://doi.org/10.1001/archopht.121.10.1392

6. Cheung C.M., Yang E., Lee W.K. et al. The natural history of polypoidal choroidal vasculopathy: A multi-center series of untreated Asian patients. Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2075–2085. https://doi.org/10.1007/s00417-015-2933-2

7. Lee M.W., Yeo I., Wong D., Ang C.L. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye (Lond). 2009;23:145–148. https://doi.org/10.1038/sj.eye.6702955

8. Akaza E., Yuzawa M., Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:39–44. https://doi.org/10.1007/s10384-010-0886-x

9. Kang H.M., Kim Y.M., Koh H.J. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155:438–447. https://doi.org/10.1016/j.ajo.2012.09.020

10. Kang H.M., Koh H.J. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156:652– 660. https://doi.org/10.1016/j.ajo.2013.05.038

11. Oishi A., Kojima H., Mandai M. et al. Comparison of the effect of ranibizumab and verteporﬁn for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013;156:644–651. https://doi.org/10.1016/j.ajo.2013.05.024

12. Taipale C., Lindholm J.M., Kaarniranta K., Tuuminen R. Comparison of two different treat-and-extend protocols with Aﬂibercept in wet age-related macular degeneration: two-year results. Adv Ther. 2020;37(5):2256–2266. https://doi.org/10.1007/s12325-020-01312-2

13. Chaikitmongkol V., Sagong M., Lai T.Y.Y., Tan G.S.W. et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Paciﬁc Vitreo-retina Society. Asia Pac J Ophthalmol (Phila). 2021;10(6):507–518. https://doi.org/10.1097/APO.0000000000000445

14. Chen L., Qu L., Gui Q., Wang S. et al. Effects of anti-vascular endothelial growth factor drugs before and after pars plana vitrectomy in patients with polypoidal choroidal vasculopathy and vitreous hemorrhage. J Ocul Pharmacol Ther. 2021;37(10):591–596. https://doi.org/10.1089/jop.2021.0039

15. Mun Y., Park K.H., Park S.J., Woo S.J. Efﬁcacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes. PLoS One. 2021;16(6):e0252006. https://doi.org/10.1371/journal.pone.0252006

16. Laugesen C.S., Ostri C., Brynskov T., Lund-Andersen H. et al. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. Acta Ophthalmol. 2017;95(1):28–32. https://doi.org/10.1111/aos.13160

17. Totuk O.M., Kanra A.Y., Bromand M.N., Tezanlayan G.K. et al. Effectiveness of intravitreal renibizumab in nonvitrectomized and vitrectomized eyes with diabetic macular edema: a two-year retrospective analysis. J Opthalmol. 2020:2561251. https://doi.org/10.1155/2020/2561251

18. Bressler S.B., Melia M., Glassman A.R. et al. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina. 2015;35:2516–2528. https://doi.org/10.1097/IAE.0000000000000617

Review

For citations:

Perevozchikov P.A., Peregudov D.V., Kuznetsova O.Yu. Trea tment of polypoid choroidal vasculopathy complicated by extensive subretinal hemorrhage. A case report. The EYE GLAZ. 2022;24(4):23-28. (In Russ.) https://doi.org/10.33791/2222-4408-2022-4-23-28

ISSN 2222-4408 (Print)
ISSN 2686-8083 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

The EYE GLAZ

Trea tment of polypoid choroidal vasculopathy complicated by extensive subretinal hemorrhage. A case report

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy